Conclusions
- This is the first and most extensive profiling study to investigate DSCR1 expression in PDAC.
- Our data show a strong association between tumor DSCR1 gene expression, several pathway alterations, immune-related gene expression, TME cell infiltration and patient survival.
- These findings suggest DSCR1 as a candidate prognostic biomarker and as a potential treatment target in PDAC.